Revvity, Inc.
RVTYHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Revvity, Inc. focuses on Diagnostics & Research services and products. Revvity, Inc. provides health sciences solutions, technologies, and services. The $12.29B market capitalization puts RVTY squarely in large-cap range for its industry. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Market Cap
$12.29B
Beta
1.09
P/E (TTM)
53.73
P/E (Fwd)
18.87
EPS (TTM)
$2.05
EPS (Fwd)
$5.84
ROE
3.2%
ROA
2.3%
Cash
$860.3M
Total Debt
$3.35B
Free CF
$509.0M
52W Change
18.1%
Annual Financials
Cash vs Debt
Revvity, Inc. carries $3.35B in total debt against $860.3M in cash reserves — debt is roughly 3.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $509.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 3.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.31B to $2.86B.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing RVTY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.